SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 ...

The decision to use b/tsDMARD monotherapy vs combination therapy with MTX when treating PsA is primarily based on patient satisfaction and drug tolerability.

The study commencement is based on previous clinical safety and efficacy data, along with robust preclinical evidence.

While some would like to see practice change to dropping aspirin earlier, these decisions will likely depend on individual ...

Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab ...

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

GV20 Therapeutics, a clinical-stage AI-based next generation biotherapeutics company, today announced presentation of ...

Response rates seen in patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy.

LONDON, England—For patients with high-risk atrial fibrillation (AF) and stable coronary artery disease, it makes sense to drop antiplatelet therapy and move forward with anticoagulation monotherapy, ...

Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated to transforming the lives of ...

Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and ...